跳至主要内容
临床试验/NCT06423287
NCT06423287Unknown不适用

Effects of Time-Restricted Eating With Lactobacillus Plantarum LP-KFY04 Supplementation on Overweight / Obese Individuals : A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial

Zhujiang Hospital1 个研究点 分布在 1 个国家目标入组 160 人开始时间: 2024年4月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
发起方
入组人数
160
试验地点
1
主要终点
Change of body weight from baseline to 12 weeks after intervention

研究概览

简要总结

With the improvement of the quality of life, multi-nutritional dietary intake today has provided people with a solid foundation for their health profiles. Time-restricted eating is found to be an effective method to prevent and control obesity, helping obese patients to lose weight in a way of reshaping the gut microbiota. Regulation of gut microbiota, as a valid weight-loss strategy, can be achieved by oral supplementation of probiotics. This study aims to evaluate the effectiveness of time-restricted eating combined with Lactobacillus Plantarum LP-KFY04 on overweight/obese population through a multi-center, randomized and double-blind clinical trial.

详细描述

With the improvement of the quality of life, multi-nutritional dietary intake today has provided people with a solid foundation for their health profiles. Time-restricted eating is found to be an effective method to prevent and control obesity, helping obese patients to lose weight in a way of reshaping the gut microbiota. Regulation of gut microbiota, as a valid weight-loss strategy, can be achieved by oral supplementation of probiotics. This study aims to evaluate the effectiveness of time-restricted eating combined with Lactobacillus Plantarum LP-KFY04 on overweight/obese population through a multi-center, randomized and double-blind clinical trial.Patients in the treatment group will be instructed to eat in an 8-hour time window (a set period of time decided by the patients) with supplementation of Lactobacillus plantarum LP-KFY04 over 12 weeks'trial.Patients in the control group will be instructed to eat in an 8-hour time window (a set period of time decided by the patients) with supplementation of placebo over 12 weeks' trial.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Men or women aged 18 to 65 years old
  • •BMI 24.0 to 40kg/m2
  • •Patients who are aware of the purpose of the trail, willing to participate in the trial and sign informed consent forms, and comply with all requirements (including those during follow-up and evaluation investigations)

排除标准

  • •History of HIV, hepatitis B or C (self-report) or active pulmonary tuberculosis;
  • •Diagnosis of type 1 or type 2 diabetes and prescribing hypoglycemic therapy
  • •History of malignant tumors
  • •Serious liver dysfunction or chronic kidney disease (aspartate aminotransferase (AST) or alanine transaminase (ALT) > 3 times the upper limit of normal, or estimated glomerular filtration rate (eGFR) < 30 ml/min/1.73 m2)
  • •History of serious cardiovascular or cerebrovascular disease (angina, myocardial infarction, or stroke) within the past 6 months
  • •History of serious gastrointestinal disease or gastrointestinal surgery within the past 12 months
  • •History of Cushing's syndrome, hypothyroidism, acromegaly, and hypothalamic obesity
  • •Smoking or have smoked within the past 3 months of the screening period
  • •Drinking alcohol or drinking more than 15 grams of alcohol per day within the past 3 months of the screening period
  • •Taking any medicine that may affect weight or metabolism within the past 6 months, including weight loss medications, antipsychotics, or other medications identified by the researchers
  • •Currently involving in a weight loss program or having significant weight change within the past 3 months (> 5% of current weight)
  • •Women who are pregnant or planning for pregnant
  • •Patients who are unable to complete 12-week follow-up (due to health conditions or immigration reasons)
  • •Patients who are unwilling or unable to provide informed consent

研究组 & 干预措施

Lactobacillus plantarum LP-KFY04

Experimental

Patients in the treatment group will be instructed to eat in an 8-hour time window (a set period of time decided by the patients) with supplementation of Lactobacillus plantarum LP-KFY04 over 12 weeks' trial.

干预措施: Lactobacillus plantarum LP-KFY04 (Dietary Supplement)

placebo

Placebo Comparator

Patients in the control group will be instructed to eat in an 8-hour time window (a set period of time decided by the patients) with supplementation of placebo over 12 weeks' trial.

干预措施: Take placebo in addition to the limited diet. (Other)

结局指标

主要结局

Change of body weight from baseline to 12 weeks after intervention

时间窗: 12 weeks

次要结局

  • Changes of waist circumference compared with baseline in subjects(12 weeks)
  • Changes of intestinal microbial composition compared with baseline in subjects(12 weeks)
  • Changes of BMI compared with baseline in subjects(12 weeks)
  • Changes of body fat percentage (BF%) compared with baseline assessed by dual-energy X-ray absorptiometry (DEXA)(12 weeks)
  • Changes of blood pressure in subjects compared with baseline(12 weeks)
  • Changes of blood lipids in subjects compared with baseline(12 weeks)
  • Changes of plasma metabolite compared with baseline in subjects(12 weeks)
  • The incidence of adverse events in two groups of subjects(12 weeks)
  • Change of subjects' HOMA-IR compared with baseline(12 weeks)
  • Changes of blood glucose in subjects compared with baseline(12 weeks)
  • Changes of intestinal microbial abundance compared with baseline in subjects(12 weeks)

研究者

发起方
Zhujiang Hospital
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验